Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Nasdaq

Atea Pharmaceuticals Reports Successful FDA Meeting and Plans Phase 3 Program for Hepatitis C Treatment

Atea Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA and plans to start patient enrollment for its global Phase 3 program for treating hepatitis C virus (HCV) in April 2025.

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and CanadaC-BEYOND Topline Results Expected ...
New Atlas

15-minute hep-C test makes same-day treatment possible

Hepatitis C is a tiny virus with a significant impact. It's a small RNA virus that spreads through the blood and infects the liver. Even though today's medicines can cure it, hepatitis C remains a ...
Yahoo

Housing Authority to open HCV Program waiting list

SAVANNAH, Ga. (WSAV) — The Housing Authority of Savannah (HAS) announced it will be opening its Section 8 Housing Choice Voucher (HCV) Program waiting list on Monday. The program provides rental ...